Glenview Trust co Invests $104,000 in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Glenview Trust co acquired a new position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 23,978 shares of the company’s stock, valued at approximately $104,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. MAI Capital Management lifted its position in Cardiff Oncology by 0.7% during the third quarter. MAI Capital Management now owns 663,363 shares of the company’s stock worth $1,771,000 after buying an additional 4,569 shares during the period. Callan Capital LLC grew its position in shares of Cardiff Oncology by 11.1% in the 4th quarter. Callan Capital LLC now owns 101,575 shares of the company’s stock worth $441,000 after acquiring an additional 10,108 shares in the last quarter. Rhumbline Advisers grew its position in shares of Cardiff Oncology by 24.0% in the 4th quarter. Rhumbline Advisers now owns 53,172 shares of the company’s stock worth $231,000 after acquiring an additional 10,290 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Cardiff Oncology by 11.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock worth $324,000 after acquiring an additional 12,503 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Cardiff Oncology in the 4th quarter worth approximately $56,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on CRDF. Piper Sandler raised their price target on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. HC Wainwright boosted their price objective on Cardiff Oncology from $13.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, February 28th.

Cardiff Oncology Stock Down 6.4 %

Shares of CRDF opened at $3.79 on Wednesday. Cardiff Oncology, Inc. has a 12-month low of $2.01 and a 12-month high of $6.42. The firm has a market capitalization of $252.13 million, a price-to-earnings ratio of -4.03 and a beta of 1.73. The stock’s 50-day moving average price is $3.98 and its 200 day moving average price is $3.38.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.